Shelton Capital Management Sells 2,429 Shares of Shire PLC (SHPG)

Shelton Capital Management reduced its position in Shire PLC (NASDAQ:SHPG) by 11.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,186 shares of the biopharmaceutical company’s stock after selling 2,429 shares during the quarter. Shelton Capital Management’s holdings in Shire were worth $2,938,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Seizert Capital Partners LLC lifted its position in shares of Shire by 13.3% in the 3rd quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock worth $1,652,000 after purchasing an additional 1,267 shares during the period. Fisher Asset Management LLC lifted its position in shares of Shire by 2.9% during the 3rd quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock valued at $8,793,000 after acquiring an additional 1,619 shares during the period. Oppenheimer Asset Management Inc. lifted its position in shares of Shire by 63.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock valued at $2,941,000 after acquiring an additional 6,917 shares during the period. Baldwin Investment Management LLC lifted its position in shares of Shire by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 23 shares during the period. Finally, Morningstar Investment Services LLC lifted its position in shares of Shire by 53.0% during the 3rd quarter. Morningstar Investment Services LLC now owns 25,882 shares of the biopharmaceutical company’s stock valued at $3,964,000 after acquiring an additional 8,969 shares during the period. 20.19% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Shire PLC (NASDAQ SHPG) traded down $1.37 during trading on Friday, hitting $155.12. 912,625 shares of the stock traded hands, compared to its average volume of 972,818. The company has a market capitalization of $47,063.12, a PE ratio of 29.05, a price-to-earnings-growth ratio of 0.90 and a beta of 1.59. Shire PLC has a 1 year low of $137.17 and a 1 year high of $192.15. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52.

Shire (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire had a net margin of 15.00% and a return on equity of 6.92%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the firm earned $3.17 EPS. analysts forecast that Shire PLC will post 15 earnings per share for the current year.

Several research firms have weighed in on SHPG. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the stock a “buy” rating in a report on Wednesday. Liberum Capital reiterated a “hold” rating on shares of Shire in a research note on Wednesday, December 20th. Royal Bank of Canada restated a “buy” rating on shares of Shire in a research report on Thursday, November 16th. FBR & Co reaffirmed a “buy” rating and set a $201.00 price objective on shares of Shire in a report on Monday, October 30th. Finally, Cowen set a $225.00 price objective on shares of Shire and gave the company a “buy” rating in a report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. Shire has a consensus rating of “Hold” and an average price target of $212.18.

COPYRIGHT VIOLATION WARNING: This report was originally published by Week Herald and is the property of of Week Herald. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://weekherald.com/2017/12/30/shelton-capital-management-decreases-holdings-in-shire-plc-shpg.html.

Shire Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply